Repligen to Report Second Quarter 2025 Financial Results
Repligen Corporation (NASDAQ:RGEN) has scheduled its second quarter 2025 financial results announcement for Tuesday, July 29, 2025. The company will release its earnings before market open and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2025.
Investors can access the conference call via phone at (800) 715-9871 (domestic) or (646) 307-1963 (international). A webcast will also be available through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay available at (800) 770-2030 (US) or (609) 800-9909 (international) using passcode 7706699.
Repligen Corporation (NASDAQ:RGEN) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per martedì 29 luglio 2025. La società pubblicherà gli utili prima dell'apertura del mercato e terrà una conference call alle 8:30 a.m. ET per discutere gli aggiornamenti aziendali e i risultati finanziari relativi ai periodi di tre e sei mesi terminati il 30 giugno 2025.
Gli investitori potranno partecipare alla conference call telefonando al (800) 715-9871 (nazionale) o al (646) 307-1963 (internazionale). Sarà disponibile anche una trasmissione in diretta tramite il sito web delle Relazioni con gli Investitori della società. Sia la chiamata che la trasmissione saranno archiviate per un accesso futuro, con la possibilità di ascoltare la registrazione al (800) 770-2030 (USA) o al (609) 800-9909 (internazionale) utilizzando il codice d’accesso 7706699.
Repligen Corporation (NASDAQ:RGEN) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el martes 29 de julio de 2025. La compañía publicará sus ganancias antes de la apertura del mercado y realizará una conferencia telefónica a las 8:30 a.m. ET para discutir actualizaciones comerciales y resultados financieros correspondientes a los períodos de tres y seis meses terminados el 30 de junio de 2025.
Los inversores pueden acceder a la conferencia telefónica llamando al (800) 715-9871 (nacional) o al (646) 307-1963 (internacional). También estará disponible una transmisión por internet a través del sitio web de Relaciones con Inversores de la compañía. Tanto la llamada como la transmisión serán archivadas para acceso futuro, con reproducción disponible llamando al (800) 770-2030 (EE.UU.) o al (609) 800-9909 (internacional) usando el código de acceso 7706699.
Repligen Corporation (NASDAQ:RGEN)은 2025년 2분기 재무 결과 발표를 2025년 7월 29일 화요일로 예정했습니다. 회사는 시장 개장 전 실적을 발표하며, 동부 표준시 오전 8시 30분에 컨퍼런스 콜을 개최하여 2025년 6월 30일 종료된 3개월 및 6개월 기간의 사업 업데이트와 재무 결과를 논의할 예정입니다.
투자자들은 국내 전화 (800) 715-9871 또는 국제 전화 (646) 307-1963를 통해 컨퍼런스 콜에 참여할 수 있습니다. 회사 투자자 관계 웹사이트를 통해 웹캐스트도 제공됩니다. 콜과 웹캐스트 모두 향후 접근을 위해 아카이브되며, 재청취는 (800) 770-2030 (미국) 또는 (609) 800-9909 (국제) 번호로 접속 시 비밀번호 7706699를 사용하여 가능합니다.
Repligen Corporation (NASDAQ:RGEN) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le mardi 29 juillet 2025. La société publiera ses résultats avant l'ouverture des marchés et tiendra une conférence téléphonique à 8h30 ET pour discuter des mises à jour commerciales et des résultats financiers des périodes de trois et six mois terminées le 30 juin 2025.
Les investisseurs peuvent accéder à la conférence téléphonique par téléphone au (800) 715-9871 (national) ou au (646) 307-1963 (international). Une diffusion en direct sera également disponible via le site web des Relations Investisseurs de la société. L'appel et la diffusion seront archivés pour un accès ultérieur, avec une rediffusion accessible au (800) 770-2030 (États-Unis) ou au (609) 800-9909 (international) en utilisant le code d'accès 7706699.
Repligen Corporation (NASDAQ:RGEN) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 29. Juli 2025 geplant. Das Unternehmen wird die Ergebnisse vor Markteröffnung veröffentlichen und um 8:30 Uhr ET eine Telefonkonferenz abhalten, um Geschäftsaktualisierungen und Finanzergebnisse für die drei- und sechsmonatigen Zeiträume zum 30. Juni 2025 zu besprechen.
Investoren können über die Telefonnummer (800) 715-9871 (national) oder (646) 307-1963 (international) an der Telefonkonferenz teilnehmen. Ein Webcast wird ebenfalls über die Investor-Relations-Website des Unternehmens verfügbar sein. Sowohl der Anruf als auch der Webcast werden für den späteren Zugriff archiviert, mit einer Wiedergabeoption unter (800) 770-2030 (USA) oder (609) 800-9909 (international) unter Verwendung des Zugangscodes 7706699.
- None.
- None.
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2025.
The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (800) 770-2030 for callers in the U.S., and (609) 800-9909 for international callers. Replay listeners must provide the passcode 7706699.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
When will Repligen (NASDAQ:RGEN) report Q2 2025 earnings?
How can I access Repligen's Q2 2025 earnings conference call?
What is the replay information for Repligen's Q2 2025 earnings call?
What period will Repligen's Q2 2025 earnings report cover?
